Type 2 Diabetes

What happens when a guideline finally reflects the complex realities of patient care? The ADA’s 2026 CKM standards aim to do just that—merging heart, kidney, and metabolic health into one actionable framework. But translating those recommendations into daily clinical decision-making isn’t always straightforward. This article walks through real-world composite cases …

What if your next diabetes appointment started before you even walked in—an algorithm already having reviewed your CGM data, flagged risks, and drafted a care plan? That’s not science fiction. It’s the emerging reality of AI-powered workflows for diabetes care, where intelligent systems work behind the scenes to support clinicians …

A patient walks into your exam room, hopeful after reading that a diabetes drug might help with memory loss, addiction, or even anxiety. You know they’re talking about GLP‑1s—but how do you respond when the science is still unfolding? As GLP‑1 receptor agonists capture public attention for much more than …

What happens when a breakthrough therapy becomes too popular for its own good? Clinics across the country are struggling to manage demand for GLP‑1 receptor agonists amid soaring prescriptions, medication shortages, and shifting insurance coverage. Without a strategy, patients fall through the cracks—and providers are left making chaotic case-by-case decisions. …

What happens when a once-costly, class-specific treatment becomes a global health priority? That’s the question raised by the World Health Organization’s latest move: recognizing GLP‑1 receptor agonists as essential medicines and issuing new recommendations for their use in obesity and diabetes care. These updated GLP‑1 WHO guidelines are more than …

What happens when medications become easier to take—but harder to track? Oral and monthly GLP‑1 therapies promise fewer injections and less hassle, yet they may also create blind spots in patient care. As these long‑acting options reshape diabetes treatment, they’re also changing how clinicians must think about follow‑up, side effect …

Peripheral artery disease (PAD) affects millions of people with type 2 diabetes worldwide, increasing the risk of cardiovascular events and limb loss. With recent research into incretin‑based therapies, particularly glucagon‑like peptide‑1 receptor agonists (GLP‑1s), clinicians are asking whether these drugs can improve outcomes in PAD patients treated with GLP‑1s, beyond …

What if the key to resolving both diabetes and liver disease lies in a single therapeutic approach? As rates of metabolic dysfunction-associated steatohepatitis (MASH) rise among people with type 2 diabetes, many clinicians are rethinking how they prioritize treatment. Rather than treating glucose and liver health in silos, combining therapies …

Artificial intelligence (AI) is transforming many aspects of diabetes care, and smart insulin management powered by AI is quickly becoming one of its most promising innovations. Tools that read continuous glucose monitor (CGM) data and suggest insulin changes are rapidly entering clinical use. But while these tools are powerful, they …

Menopause marks a major transition in a woman’s life, defined not only by the end of menstrual cycles but also by profound hormonal and metabolic changes. One often under‑recognized shift is the acceleration of cardiometabolic risk. Women in midlife frequently experience increased central adiposity, changes in glucose regulation, rising blood …